Verified January 2012 by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received on November 20, 2008. Last Updated on January 26, 2012
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS).
Se puede apreciar ya que hay centros con el ensayo completado :
Locations :
United States, New Mexico
Completed
Albuquerque, New Mexico, United States
United States, Pennsylvania
Completed
Philadelphia, Pennsylvania, United States
Spain :
Completed
Barcelona, Spain
Completed
Valencia N/A, Spain
Sponsors and Collaborators :
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PharmaMar
Investigators :
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.